{"id": "article-36546_0", "title": "Substance Use in Pregnancy -- Continuing Education Activity", "content": "Substance use and substance use disorders in pregnancy are common and linked with multiple obstetric and neonatal adverse outcomes. Ideally, all pregnant women should be screened, and those with positive screens should be promptly diagnosed and treated to avoid the morbidity and mortality associated with continued substance use during pregnancy. This activity reviews the adverse outcomes associated with the most commonly used substances and the need to collaborate with an interprofessional team to counsel, appropriately treat, and support women during their pregnancies for better outcomes.", "contents": "Substance Use in Pregnancy -- Continuing Education Activity. Substance use and substance use disorders in pregnancy are common and linked with multiple obstetric and neonatal adverse outcomes. Ideally, all pregnant women should be screened, and those with positive screens should be promptly diagnosed and treated to avoid the morbidity and mortality associated with continued substance use during pregnancy. This activity reviews the adverse outcomes associated with the most commonly used substances and the need to collaborate with an interprofessional team to counsel, appropriately treat, and support women during their pregnancies for better outcomes."}
{"id": "article-36546_1", "title": "Substance Use in Pregnancy -- Continuing Education Activity", "content": "Objectives: Identify the common adverse outcomes associated with the most commonly used substances during pregnancy. Review the use of validated screening instruments to better identify substance use in pregnancy. Implement the recommended treatments for substance use disorders in pregnancy. Collaborate with an interprofessional team to counsel and support women during treatment for substance use during pregnancy for better outcomes. Access free multiple choice questions on this topic.", "contents": "Substance Use in Pregnancy -- Continuing Education Activity. Objectives: Identify the common adverse outcomes associated with the most commonly used substances during pregnancy. Review the use of validated screening instruments to better identify substance use in pregnancy. Implement the recommended treatments for substance use disorders in pregnancy. Collaborate with an interprofessional team to counsel and support women during treatment for substance use during pregnancy for better outcomes. Access free multiple choice questions on this topic."}
{"id": "article-36546_2", "title": "Substance Use in Pregnancy -- Introduction", "content": "Perinatal substance use\u00a0is a significant public health issue in the United States (US) and worldwide. In the US, 40% of\u00a0persons with a lifetime drug use disorder and 26% with a combined alcohol and drug use disorder during the prior\u00a0year are women. They are at the highest risk for\u00a0substance use disorder during their reproductive years, and substance use during pregnancy is prevalent.\u00a0The most\u00a0frequently used substances in pregnancy are tobacco, alcohol, and marijuana, followed by cocaine and opioids.\u00a0Use in pregnancy is associated with multiple adverse outcomes for the mother\u00a0and their child.", "contents": "Substance Use in Pregnancy -- Introduction. Perinatal substance use\u00a0is a significant public health issue in the United States (US) and worldwide. In the US, 40% of\u00a0persons with a lifetime drug use disorder and 26% with a combined alcohol and drug use disorder during the prior\u00a0year are women. They are at the highest risk for\u00a0substance use disorder during their reproductive years, and substance use during pregnancy is prevalent.\u00a0The most\u00a0frequently used substances in pregnancy are tobacco, alcohol, and marijuana, followed by cocaine and opioids.\u00a0Use in pregnancy is associated with multiple adverse outcomes for the mother\u00a0and their child."}
{"id": "article-36546_3", "title": "Substance Use in Pregnancy -- Introduction", "content": "Universal screening is recommended,\u00a0with access to effective interventions if indicated. However, pregnant women who use substances often feel stigmatized, and barriers to evidence-based treatments exist.\u00a0This activity will\u00a0include a discussion of legal and psychosocial issues and the importance of the interprofessional team in ensuring healthy outcomes for\u00a0women\u00a0who use substances during pregnancy and their children.", "contents": "Substance Use in Pregnancy -- Introduction. Universal screening is recommended,\u00a0with access to effective interventions if indicated. However, pregnant women who use substances often feel stigmatized, and barriers to evidence-based treatments exist.\u00a0This activity will\u00a0include a discussion of legal and psychosocial issues and the importance of the interprofessional team in ensuring healthy outcomes for\u00a0women\u00a0who use substances during pregnancy and their children."}
{"id": "article-36546_4", "title": "Substance Use in Pregnancy -- Etiology", "content": "Most women\u00a0who use substances decrease their use during pregnancy. In general, women do not choose to begin using any potentially toxic substances once they know they are pregnant. Those who can\u00a0quit on their own usually do so,\u00a0which is the distinguishing factor between substance use and substance use disorder (SUD).", "contents": "Substance Use in Pregnancy -- Etiology. Most women\u00a0who use substances decrease their use during pregnancy. In general, women do not choose to begin using any potentially toxic substances once they know they are pregnant. Those who can\u00a0quit on their own usually do so,\u00a0which is the distinguishing factor between substance use and substance use disorder (SUD)."}
{"id": "article-36546_5", "title": "Substance Use in Pregnancy -- Etiology", "content": "The etiology of SUD is multifactorial, and pregnant women are no different than the general population. Many genetic, environmental, psychological, biological, and socioeconomic factors contribute to individual susceptibility. [1] Tobacco and alcohol are often readily available and perceived as safe\u00a0because they are legal.\u00a0Prescription opioids, including those prescribed after delivery, contribute to opioid use disorder (OUD) by exposing women to addictive medications and making available\u00a0leftover pills that can be misused or diverted. [2]", "contents": "Substance Use in Pregnancy -- Etiology. The etiology of SUD is multifactorial, and pregnant women are no different than the general population. Many genetic, environmental, psychological, biological, and socioeconomic factors contribute to individual susceptibility. [1] Tobacco and alcohol are often readily available and perceived as safe\u00a0because they are legal.\u00a0Prescription opioids, including those prescribed after delivery, contribute to opioid use disorder (OUD) by exposing women to addictive medications and making available\u00a0leftover pills that can be misused or diverted. [2]"}
{"id": "article-36546_6", "title": "Substance Use in Pregnancy -- Etiology", "content": "Other prescribed controlled substances like\u00a0amphetamines and barbiturates can\u00a0also lead to dependence. Illicit drugs such as heroin may be easy to obtain by those with SUD and drug-seeking behaviors. Other conditions such as poor nutrition, needle sharing, lack of safe housing, poverty, low educational level, and\u00a0intimate partner violence\u00a0are associated with\u00a0the diagnosis of SUD.\u00a0Patient-report surveys investigating the\u00a0influence of the environment\u00a0demonstrate\u00a0increased\u00a0levels of alcohol and drug use in urban\u00a0locales and communities with higher proportions of adolescents, young adults, and immigrants. [1] [3]", "contents": "Substance Use in Pregnancy -- Etiology. Other prescribed controlled substances like\u00a0amphetamines and barbiturates can\u00a0also lead to dependence. Illicit drugs such as heroin may be easy to obtain by those with SUD and drug-seeking behaviors. Other conditions such as poor nutrition, needle sharing, lack of safe housing, poverty, low educational level, and\u00a0intimate partner violence\u00a0are associated with\u00a0the diagnosis of SUD.\u00a0Patient-report surveys investigating the\u00a0influence of the environment\u00a0demonstrate\u00a0increased\u00a0levels of alcohol and drug use in urban\u00a0locales and communities with higher proportions of adolescents, young adults, and immigrants. [1] [3]"}
{"id": "article-36546_7", "title": "Substance Use in Pregnancy -- Epidemiology", "content": "Between 2005 and 2014, 11.5% of adolescent and 8.7% of adult pregnant women reported drinking alcohol, and 23% of adolescent and 14.9% of adult women reported using tobacco. [4] A US national survey in 2012 showed that 5.9% of pregnant women reported using illicit drugs, 8.5% reported drinking alcohol, and 15.9% reported smoking cigarettes during pregnancy.\u00a0Similar use and fetal exposure to these substances have been reported in Europe and Australia. [5]", "contents": "Substance Use in Pregnancy -- Epidemiology. Between 2005 and 2014, 11.5% of adolescent and 8.7% of adult pregnant women reported drinking alcohol, and 23% of adolescent and 14.9% of adult women reported using tobacco. [4] A US national survey in 2012 showed that 5.9% of pregnant women reported using illicit drugs, 8.5% reported drinking alcohol, and 15.9% reported smoking cigarettes during pregnancy.\u00a0Similar use and fetal exposure to these substances have been reported in Europe and Australia. [5]"}
{"id": "article-36546_8", "title": "Substance Use in Pregnancy -- Epidemiology", "content": "Retrospective reviews demonstrate that 2.5% of all pregnant women and about 20% of those with US Medicaid insurance received at least one prescription for an opioid during pregnancy. [6] Most pregnancies in mothers with OUD are unplanned. [7] Polysubstance use is\u00a0frequent\u00a0during pregnancy, similar to the general population. There is a documented decrease in cigarette, alcohol, marijuana, and cocaine use during pregnancy, with most women quitting or cutting back. [8]", "contents": "Substance Use in Pregnancy -- Epidemiology. Retrospective reviews demonstrate that 2.5% of all pregnant women and about 20% of those with US Medicaid insurance received at least one prescription for an opioid during pregnancy. [6] Most pregnancies in mothers with OUD are unplanned. [7] Polysubstance use is\u00a0frequent\u00a0during pregnancy, similar to the general population. There is a documented decrease in cigarette, alcohol, marijuana, and cocaine use during pregnancy, with most women quitting or cutting back. [8]"}
{"id": "article-36546_9", "title": "Substance Use in Pregnancy -- Epidemiology", "content": "SUD is\u00a0rarely an isolated diagnosis. It is associated with increased rates of psychiatric conditions, including major depressive, bipolar, posttraumatic stress, and panic disorder. [9] Comorbid human immunodeficiency virus (HIV), hepatitis B and C, tuberculosis, and sexually transmitted infections\u00a0occur due to an association with multiple sex partners, sharing drug paraphernalia, homelessness, and increased incarceration rates. [10] [11]", "contents": "Substance Use in Pregnancy -- Epidemiology. SUD is\u00a0rarely an isolated diagnosis. It is associated with increased rates of psychiatric conditions, including major depressive, bipolar, posttraumatic stress, and panic disorder. [9] Comorbid human immunodeficiency virus (HIV), hepatitis B and C, tuberculosis, and sexually transmitted infections\u00a0occur due to an association with multiple sex partners, sharing drug paraphernalia, homelessness, and increased incarceration rates. [10] [11]"}
{"id": "article-36546_10", "title": "Substance Use in Pregnancy -- Pathophysiology", "content": "Substance use and SUD in pregnancy are associated with\u00a0significant\u00a0maternal, fetal, and neonatal pathology, depending on the substances involved. Explaining the pathophysiological consequences of each substance is beyond the scope of this activity.", "contents": "Substance Use in Pregnancy -- Pathophysiology. Substance use and SUD in pregnancy are associated with\u00a0significant\u00a0maternal, fetal, and neonatal pathology, depending on the substances involved. Explaining the pathophysiological consequences of each substance is beyond the scope of this activity."}
{"id": "article-36546_11", "title": "Substance Use in Pregnancy -- History and Physical", "content": "The fifth edition of the\u00a0Diagnostic and Statistical Manual of Mental Disorders (DSM-5) combined the substance abuse and dependence criteria to\u00a0diagnose SUD. [12] The presence of two or more in the preceding 12 months is diagnostic of SUD: hazardous use social/interpersonal problems\u00a0due to using neglect\u00a0of expected roles withdrawal tolerance using\u00a0more or for longer than intended repeated attempts to quit related physical/psychological problems craving use preferred over other activities", "contents": "Substance Use in Pregnancy -- History and Physical. The fifth edition of the\u00a0Diagnostic and Statistical Manual of Mental Disorders (DSM-5) combined the substance abuse and dependence criteria to\u00a0diagnose SUD. [12] The presence of two or more in the preceding 12 months is diagnostic of SUD: hazardous use social/interpersonal problems\u00a0due to using neglect\u00a0of expected roles withdrawal tolerance using\u00a0more or for longer than intended repeated attempts to quit related physical/psychological problems craving use preferred over other activities"}
{"id": "article-36546_12", "title": "Substance Use in Pregnancy -- History and Physical", "content": "A comprehensive medical history and a complete physical examination are the first steps in establishing the diagnosis of SUD. Some pregnant women readily admit to substance use,\u00a0but others may be reluctant to disclose this sensitive information due to fear of repercussions, judgmental treatment, and social services involvement. When a stated history of substance use is absent, other features of the medical history can\u00a0point to possible SUD, including a history of endocarditis, HIV, hepatitis C, sexual and/or physical abuse, and psychiatric conditions. A pregnant woman with late or no prenatal care may have avoided\u00a0appointments due to concerns about revealing\u00a0her\u00a0substance use and the perceived adverse consequences. Many fear arrest, prosecution, and loss of child custody.", "contents": "Substance Use in Pregnancy -- History and Physical. A comprehensive medical history and a complete physical examination are the first steps in establishing the diagnosis of SUD. Some pregnant women readily admit to substance use,\u00a0but others may be reluctant to disclose this sensitive information due to fear of repercussions, judgmental treatment, and social services involvement. When a stated history of substance use is absent, other features of the medical history can\u00a0point to possible SUD, including a history of endocarditis, HIV, hepatitis C, sexual and/or physical abuse, and psychiatric conditions. A pregnant woman with late or no prenatal care may have avoided\u00a0appointments due to concerns about revealing\u00a0her\u00a0substance use and the perceived adverse consequences. Many fear arrest, prosecution, and loss of child custody."}
{"id": "article-36546_13", "title": "Substance Use in Pregnancy -- History and Physical", "content": "Physical examination begins with vital signs, with hypertension being a clue\u00a0for possible cocaine or amphetamine use. Nasal septal perforation may be an additional clue\u00a0for cocaine use. An underweight patient may be malnourished due to drugs or alcohol. Clinical staff, including medical assistants, nurses, nurse practitioners, physician assistants, and physicians, should\u00a0observe the patient's general appearance. Women who\u00a0are obtunded, agitated, or sleepy may be under the influence of substances. Dilated or\u00a0constricted pupils and injection marks\u00a0on the skin\u00a0suggest possible opioid use. Bruises should elicit questions about maltreatment. If a pregnant woman smells strongly of tobacco, alcohol, or marijuana, she should be asked specifically about these substances in a confidential setting. Another frequent but nonspecific physical finding is poor dentition.", "contents": "Substance Use in Pregnancy -- History and Physical. Physical examination begins with vital signs, with hypertension being a clue\u00a0for possible cocaine or amphetamine use. Nasal septal perforation may be an additional clue\u00a0for cocaine use. An underweight patient may be malnourished due to drugs or alcohol. Clinical staff, including medical assistants, nurses, nurse practitioners, physician assistants, and physicians, should\u00a0observe the patient's general appearance. Women who\u00a0are obtunded, agitated, or sleepy may be under the influence of substances. Dilated or\u00a0constricted pupils and injection marks\u00a0on the skin\u00a0suggest possible opioid use. Bruises should elicit questions about maltreatment. If a pregnant woman smells strongly of tobacco, alcohol, or marijuana, she should be asked specifically about these substances in a confidential setting. Another frequent but nonspecific physical finding is poor dentition."}
{"id": "article-36546_14", "title": "Substance Use in Pregnancy -- Evaluation", "content": "Substance use in pregnancy is a common condition with substantial complications. A thorough medical history and physical examination will often lead to a diagnosis of SUD or reveal concerning substance use that does not meet the DSM-5 criteria for SUD. However, many women will not disclose sensitive information about their substance use, so clinicians\u00a0must rely on other methods to identify\u00a0those at risk.", "contents": "Substance Use in Pregnancy -- Evaluation. Substance use in pregnancy is a common condition with substantial complications. A thorough medical history and physical examination will often lead to a diagnosis of SUD or reveal concerning substance use that does not meet the DSM-5 criteria for SUD. However, many women will not disclose sensitive information about their substance use, so clinicians\u00a0must rely on other methods to identify\u00a0those at risk."}
{"id": "article-36546_15", "title": "Substance Use in Pregnancy -- Evaluation", "content": "The American College of Obstetricians and Gynecologists (ACOG) recommends early, universal screening for substance use as part of comprehensive prenatal care in partnership with pregnant women. [13] In fact, most developed countries advocate for universal screening. [14] If women are screened only when a medical provider suspects drug or alcohol use, many patients will be missed. A validated screening instrument that is easy to administer, acceptable, and economical should be used. Barriers exist, including the perception that screening will offend women and\u00a0insufficient time during an office visit to counsel and refer those whose screen is positive. In general, no\u00a0screening instrument is superior; three free and easy-to-use screens are the NIDA Quick Screen, 4 Ps, and CRAFFT (for women\u00a0younger than 27). [15] The T-ACE and T-ACER 3 screens are specific for alcohol use in pregnancy. [16] These validated screening\u00a0instruments\u00a0are readily available online. Trained clinical staff, including medical assistants and nurses, can\u00a0administer the selected screening instrument. ACOG recommends an initial screening at the first prenatal visit, and many practitioners repeat screening at designated intervals during\u00a0subsequent visits.", "contents": "Substance Use in Pregnancy -- Evaluation. The American College of Obstetricians and Gynecologists (ACOG) recommends early, universal screening for substance use as part of comprehensive prenatal care in partnership with pregnant women. [13] In fact, most developed countries advocate for universal screening. [14] If women are screened only when a medical provider suspects drug or alcohol use, many patients will be missed. A validated screening instrument that is easy to administer, acceptable, and economical should be used. Barriers exist, including the perception that screening will offend women and\u00a0insufficient time during an office visit to counsel and refer those whose screen is positive. In general, no\u00a0screening instrument is superior; three free and easy-to-use screens are the NIDA Quick Screen, 4 Ps, and CRAFFT (for women\u00a0younger than 27). [15] The T-ACE and T-ACER 3 screens are specific for alcohol use in pregnancy. [16] These validated screening\u00a0instruments\u00a0are readily available online. Trained clinical staff, including medical assistants and nurses, can\u00a0administer the selected screening instrument. ACOG recommends an initial screening at the first prenatal visit, and many practitioners repeat screening at designated intervals during\u00a0subsequent visits."}
{"id": "article-36546_16", "title": "Substance Use in Pregnancy -- Evaluation", "content": "A\u00a0positive screen cannot be considered diagnostic of SUD in pregnancy.\u00a0False positive and false negative results occur, and screening may reveal occasional substance use rather than SUD. The clinician's next step is a conversation regarding the frequency of substance use and\u00a0whether there is any current use.\u00a0It is essential to\u00a0counsel pregnant women about the risks to\u00a0themselves and their\u00a0children and discourage further use. When SUD is suspected or confirmed,\u00a0it is essential to provide information about local resources for counseling and treatment in a nonjudgmental manner. Medical providers should never assume family members or significant others know about a woman's substance use, and respecting patient confidentiality is of utmost importance. Clinicians should also be knowledgeable about local\u00a0and state reporting requirements. SUD is a medical condition, not a moral failing, and punitive attitudes\u00a0can negatively impact maternal\u00a0and neonatal outcomes. Women with SUD who feel stigmatized may avoid continuing essential prenatal care.", "contents": "Substance Use in Pregnancy -- Evaluation. A\u00a0positive screen cannot be considered diagnostic of SUD in pregnancy.\u00a0False positive and false negative results occur, and screening may reveal occasional substance use rather than SUD. The clinician's next step is a conversation regarding the frequency of substance use and\u00a0whether there is any current use.\u00a0It is essential to\u00a0counsel pregnant women about the risks to\u00a0themselves and their\u00a0children and discourage further use. When SUD is suspected or confirmed,\u00a0it is essential to provide information about local resources for counseling and treatment in a nonjudgmental manner. Medical providers should never assume family members or significant others know about a woman's substance use, and respecting patient confidentiality is of utmost importance. Clinicians should also be knowledgeable about local\u00a0and state reporting requirements. SUD is a medical condition, not a moral failing, and punitive attitudes\u00a0can negatively impact maternal\u00a0and neonatal outcomes. Women with SUD who feel stigmatized may avoid continuing essential prenatal care."}
{"id": "article-36546_17", "title": "Substance Use in Pregnancy -- Evaluation", "content": "Screening is often confused with drug or alcohol testing. Universal screening, but not routine drug or alcohol toxicology testing, is recommended in pregnant women. Screening\u00a0is a test used for at-risk populations, including those without symptoms. However, testing for biological markers of substance use may be indicated in specific situations, especially when objective\u00a0or specific information about multiple substances is required. Urine, hair, and meconium samples have shown adequate sensitivity as biological markers of substance use. Urine drug screening mainly detects recent use. [17] Neonatal hair and meconium testing can reveal intrauterine use\u00a0in the second and third trimesters. [18] Maternal consent, except in life-threatening situations, is required before performing drug testing during pregnancy. [18]", "contents": "Substance Use in Pregnancy -- Evaluation. Screening is often confused with drug or alcohol testing. Universal screening, but not routine drug or alcohol toxicology testing, is recommended in pregnant women. Screening\u00a0is a test used for at-risk populations, including those without symptoms. However, testing for biological markers of substance use may be indicated in specific situations, especially when objective\u00a0or specific information about multiple substances is required. Urine, hair, and meconium samples have shown adequate sensitivity as biological markers of substance use. Urine drug screening mainly detects recent use. [17] Neonatal hair and meconium testing can reveal intrauterine use\u00a0in the second and third trimesters. [18] Maternal consent, except in life-threatening situations, is required before performing drug testing during pregnancy. [18]"}
{"id": "article-36546_18", "title": "Substance Use in Pregnancy -- Evaluation", "content": "Mandated biological testing may be required for women in treatment programs or involved with the legal system. Drug testing does not\u00a0distinguish between regular and occasional substance use and should be based\u00a0on medical criteria rather than demographic profiling. Testing in the hospital\u00a0during labor and delivery\u00a0must occur before administering\u00a0prescription medications that may produce a positive result. Each community has trends in drug use,\u00a0which should be reflected in local and hospital laboratories' testing panels. False-positive test\u00a0results have been linked to ingesting poppy seeds and dextromethorphan. [19] [20] False-negative results occur when patients substitute someone else's urine for their own. An astute laboratory technician or nurse may notice that the\u00a0sample\u00a0provided by the patient is cool or at room temperature rather than body temperature and question the specimen's origin.", "contents": "Substance Use in Pregnancy -- Evaluation. Mandated biological testing may be required for women in treatment programs or involved with the legal system. Drug testing does not\u00a0distinguish between regular and occasional substance use and should be based\u00a0on medical criteria rather than demographic profiling. Testing in the hospital\u00a0during labor and delivery\u00a0must occur before administering\u00a0prescription medications that may produce a positive result. Each community has trends in drug use,\u00a0which should be reflected in local and hospital laboratories' testing panels. False-positive test\u00a0results have been linked to ingesting poppy seeds and dextromethorphan. [19] [20] False-negative results occur when patients substitute someone else's urine for their own. An astute laboratory technician or nurse may notice that the\u00a0sample\u00a0provided by the patient is cool or at room temperature rather than body temperature and question the specimen's origin."}
{"id": "article-36546_19", "title": "Substance Use in Pregnancy -- Treatment / Management", "content": "The optimal management strategy for\u00a0pregnant women with substance use or\u00a0SUD begins with comprehensive prenatal care.\u00a0The next step is counseling and educating\u00a0them\u00a0about the consequences of tobacco, alcohol,\u00a0and drug use\u00a0related to\u00a0themself\u00a0and their unborn\u00a0child and encouraging\u00a0them to discontinue or reduce usage. Motivational interviewing and brief intervention rather than a judgmental or punitive approach are more likely to produce positive behavioral change. All women with SUD should be referred to the appropriate provider without delay for comprehensive behavioral and medical treatment.", "contents": "Substance Use in Pregnancy -- Treatment / Management. The optimal management strategy for\u00a0pregnant women with substance use or\u00a0SUD begins with comprehensive prenatal care.\u00a0The next step is counseling and educating\u00a0them\u00a0about the consequences of tobacco, alcohol,\u00a0and drug use\u00a0related to\u00a0themself\u00a0and their unborn\u00a0child and encouraging\u00a0them to discontinue or reduce usage. Motivational interviewing and brief intervention rather than a judgmental or punitive approach are more likely to produce positive behavioral change. All women with SUD should be referred to the appropriate provider without delay for comprehensive behavioral and medical treatment."}
{"id": "article-36546_20", "title": "Substance Use in Pregnancy -- Treatment / Management", "content": "Treatment\u00a0of all types of SUD reduces the risk of relapse and improves pregnancy outcomes. ACOG recommends that pregnant women who smoke or use nicotine and tobacco products quit. Babies born to women who abstain by 15 weeks of gestation benefit the most. When behavioral counseling does not\u00a0result in smoking cessation, varenicline, bupropion, and nicotine replacement can be considered, but these treatments lack safety data for use in pregnancy. Varenicline and bupropion are both FDA category C medications. Nicotine replacement during pregnancy has not been\u00a0proven to result in long-term smoking cessation. [21]", "contents": "Substance Use in Pregnancy -- Treatment / Management. Treatment\u00a0of all types of SUD reduces the risk of relapse and improves pregnancy outcomes. ACOG recommends that pregnant women who smoke or use nicotine and tobacco products quit. Babies born to women who abstain by 15 weeks of gestation benefit the most. When behavioral counseling does not\u00a0result in smoking cessation, varenicline, bupropion, and nicotine replacement can be considered, but these treatments lack safety data for use in pregnancy. Varenicline and bupropion are both FDA category C medications. Nicotine replacement during pregnancy has not been\u00a0proven to result in long-term smoking cessation. [21]"}
{"id": "article-36546_21", "title": "Substance Use in Pregnancy -- Treatment / Management", "content": "Patients with alcohol or benzodiazepine use disorder can be managed with detoxification using a diazepam or lorazepam taper. [18] Approved medications for alcohol use disorder include naltrexone, disulfiram, and acamprosate. However, they are category C medications with no human data to support safety during pregnancy, and animal studies\u00a0show adverse and possible teratogenic effects. [22] Alcohol withdrawal syndrome is dangerous and potentially life-threatening, resulting in seizures and delirium tremens, and patients with withdrawal should\u00a0receive\u00a0inpatient detoxification. [23]", "contents": "Substance Use in Pregnancy -- Treatment / Management. Patients with alcohol or benzodiazepine use disorder can be managed with detoxification using a diazepam or lorazepam taper. [18] Approved medications for alcohol use disorder include naltrexone, disulfiram, and acamprosate. However, they are category C medications with no human data to support safety during pregnancy, and animal studies\u00a0show adverse and possible teratogenic effects. [22] Alcohol withdrawal syndrome is dangerous and potentially life-threatening, resulting in seizures and delirium tremens, and patients with withdrawal should\u00a0receive\u00a0inpatient detoxification. [23]"}
{"id": "article-36546_22", "title": "Substance Use in Pregnancy -- Treatment / Management", "content": "Medication-assisted treatment is the standard of care for pregnant women with OUD. Although some women choose\u00a0medically supervised withdrawal, current guidelines recommend treatment with methadone or buprenorphine. There is a higher rate of relapse during pregnancy in women who\u00a0elect detoxification rather than medication-assisted treatment. [24] Naltrexone, an opioid receptor antagonist, is also approved for OUD, but insufficient data exist to recommend initiating the medication during pregnancy. However, when a pregnant woman is already treated with naltrexone, she may elect to continue it\u00a0after\u00a0reviewing\u00a0potential risks and benefits with her clinician and with close medical supervision. [25]", "contents": "Substance Use in Pregnancy -- Treatment / Management. Medication-assisted treatment is the standard of care for pregnant women with OUD. Although some women choose\u00a0medically supervised withdrawal, current guidelines recommend treatment with methadone or buprenorphine. There is a higher rate of relapse during pregnancy in women who\u00a0elect detoxification rather than medication-assisted treatment. [24] Naltrexone, an opioid receptor antagonist, is also approved for OUD, but insufficient data exist to recommend initiating the medication during pregnancy. However, when a pregnant woman is already treated with naltrexone, she may elect to continue it\u00a0after\u00a0reviewing\u00a0potential risks and benefits with her clinician and with close medical supervision. [25]"}
{"id": "article-36546_23", "title": "Substance Use in Pregnancy -- Treatment / Management", "content": "Medication-assisted treatment suppresses cravings and withdrawal symptoms, and patients are less likely to use illicit\u00a0substances when enrolled in a treatment program. Pregnant women\u00a0better adhere to prenatal care recommendations and\u00a0experience\u00a0fewer complications associated with intravenous drug use, such as overdose and infection. However, many pregnant women with OUD\u00a0struggle to access medication-assisted treatment compared to their non-pregnant peers, especially those living in rural areas, non-English speakers, and those not covered by health insurance. [24] [26] [27]", "contents": "Substance Use in Pregnancy -- Treatment / Management. Medication-assisted treatment suppresses cravings and withdrawal symptoms, and patients are less likely to use illicit\u00a0substances when enrolled in a treatment program. Pregnant women\u00a0better adhere to prenatal care recommendations and\u00a0experience\u00a0fewer complications associated with intravenous drug use, such as overdose and infection. However, many pregnant women with OUD\u00a0struggle to access medication-assisted treatment compared to their non-pregnant peers, especially those living in rural areas, non-English speakers, and those not covered by health insurance. [24] [26] [27]"}
{"id": "article-36546_24", "title": "Substance Use in Pregnancy -- Treatment / Management", "content": "The decision to\u00a0prescribe either buprenorphine or methadone depends on many factors, including the availability of treatment programs and whether the patient prefers daily supervised medication appointments or a prescription to be taken at home. [28] [29] Methadone is a long-acting, full mu-receptor agonist and, in the US, must be dispensed at a federally accredited opioid treatment program under direct\u00a0supervision. Patients require access to a local program and reliable transportation. Methadone reduces HIV risks and fetal mortality and increases birth weight and adherence to prenatal care.\u00a0Buprenorphine is a partial mu-receptor agonist and can be prescribed in office-based settings. Patients may take oral or sublingual\u00a0buprenorphine at home, with regular follow-up office visits. They do not\u00a0need daily transportation to a treatment facility, but there is a risk of medication diversion and non-compliance. Prescribers must\u00a0know\u00a0about\u00a0local resources and patient-specific factors to determine\u00a0the best treatment plan for each patient.", "contents": "Substance Use in Pregnancy -- Treatment / Management. The decision to\u00a0prescribe either buprenorphine or methadone depends on many factors, including the availability of treatment programs and whether the patient prefers daily supervised medication appointments or a prescription to be taken at home. [28] [29] Methadone is a long-acting, full mu-receptor agonist and, in the US, must be dispensed at a federally accredited opioid treatment program under direct\u00a0supervision. Patients require access to a local program and reliable transportation. Methadone reduces HIV risks and fetal mortality and increases birth weight and adherence to prenatal care.\u00a0Buprenorphine is a partial mu-receptor agonist and can be prescribed in office-based settings. Patients may take oral or sublingual\u00a0buprenorphine at home, with regular follow-up office visits. They do not\u00a0need daily transportation to a treatment facility, but there is a risk of medication diversion and non-compliance. Prescribers must\u00a0know\u00a0about\u00a0local resources and patient-specific factors to determine\u00a0the best treatment plan for each patient."}
{"id": "article-36546_25", "title": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and will integrate substance use disorder treatment across healthcare settings.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. The Mainstreaming Addiction Treatment (MAT) Act provision updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all health care providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder (OUD), just as they prescribe other essential medications. The MAT Act is intended to help destigmatize a standard of care for OUD and will integrate substance use disorder treatment across healthcare settings."}
{"id": "article-36546_26", "title": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law, and SAMHSA encourages them to do so. Prescribers who were registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed on the part of registrants.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for OUD in their practice if permitted by applicable state law, and SAMHSA encourages them to do so. Prescribers who were registered as DATA-Waiver prescribers will receive a new DEA registration certificate reflecting this change; no action is needed on the part of registrants."}
{"id": "article-36546_27", "title": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "There are no longer any limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. There are no longer any limits on the number of patients with OUD that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required."}
{"id": "article-36546_28", "title": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act", "content": "Pharmacy staff can now fill buprenorphine prescriptions using the prescribing authority's DEA number and does not need a DATA 2000 waiver from the prescriber. However, depending on the pharmacy, the dispensing software may still require the X-Waiver information in order to proceed. Practitioners are still required to comply with any applicable state limits regarding the treatment of patients with OUD.\u00a0 Contact information for State Opioid Treatment Authorities can be found here: https://www.samhsa.gov/medicationassisted-treatment/sota.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Mainstreaming Addiction Treatment (MAT) Act. Pharmacy staff can now fill buprenorphine prescriptions using the prescribing authority's DEA number and does not need a DATA 2000 waiver from the prescriber. However, depending on the pharmacy, the dispensing software may still require the X-Waiver information in order to proceed. Practitioners are still required to comply with any applicable state limits regarding the treatment of patients with OUD.\u00a0 Contact information for State Opioid Treatment Authorities can be found here: https://www.samhsa.gov/medicationassisted-treatment/sota."}
{"id": "article-36546_29", "title": "Substance Use in Pregnancy -- Treatment / Management -- Neonatal opioid withdrawal syndrome (NOWS)", "content": "Neonatal opioid withdrawal syndrome (NOWS), previously referred to as neonatal abstinence syndrome (NAS), is an expected and\u00a0manageable condition in newborns with\u00a0prenatal opioid exposure. Treatment with\u00a0methadone and buprenorphine during pregnancy can decrease the severity of NOWS. Some studies demonstrate that newborns exposed to prenatal buprenorphine require less medication and have a shorter\u00a0hospital stay than\u00a0those exposed to methadone. [30] They may also have a slightly improved birth weight and gestational age. [31]", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Neonatal opioid withdrawal syndrome (NOWS). Neonatal opioid withdrawal syndrome (NOWS), previously referred to as neonatal abstinence syndrome (NAS), is an expected and\u00a0manageable condition in newborns with\u00a0prenatal opioid exposure. Treatment with\u00a0methadone and buprenorphine during pregnancy can decrease the severity of NOWS. Some studies demonstrate that newborns exposed to prenatal buprenorphine require less medication and have a shorter\u00a0hospital stay than\u00a0those exposed to methadone. [30] They may also have a slightly improved birth weight and gestational age. [31]"}
{"id": "article-36546_30", "title": "Substance Use in Pregnancy -- Treatment / Management -- Neonatal opioid withdrawal syndrome (NOWS)", "content": "Medication-assisted treatment has not been associated with congenital malformations, and studies show minimal to no long-term neurodevelopmental adverse outcomes in exposed infants. [32] [33] Symptom onset often occurs\u00a0within 12 to 24 hours with heroin exposure but between 48 and 72 hours with medication-assisted treatment. Occasionally, infants do not exhibit symptoms until aged 5 to 7 days. Some studies correlate the dose of\u00a0medication-assisted treatment with the severity and incidence of NOWS, but others find no association. [34] [35]", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Neonatal opioid withdrawal syndrome (NOWS). Medication-assisted treatment has not been associated with congenital malformations, and studies show minimal to no long-term neurodevelopmental adverse outcomes in exposed infants. [32] [33] Symptom onset often occurs\u00a0within 12 to 24 hours with heroin exposure but between 48 and 72 hours with medication-assisted treatment. Occasionally, infants do not exhibit symptoms until aged 5 to 7 days. Some studies correlate the dose of\u00a0medication-assisted treatment with the severity and incidence of NOWS, but others find no association. [34] [35]"}
{"id": "article-36546_31", "title": "Substance Use in Pregnancy -- Treatment / Management -- Neonatal opioid withdrawal syndrome (NOWS)", "content": "Women who begin medication-assisted treatment before or early in pregnancy are more likely to receive comprehensive prenatal care, follow medical recommendations, and deliver healthier babies. They are also less likely to relapse\u00a0or\u00a0acquire sexually transmitted infections. Medication-assisted treatment should be readily available to all pregnant women identified with OUD to improve maternal and infant outcomes.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Neonatal opioid withdrawal syndrome (NOWS). Women who begin medication-assisted treatment before or early in pregnancy are more likely to receive comprehensive prenatal care, follow medical recommendations, and deliver healthier babies. They are also less likely to relapse\u00a0or\u00a0acquire sexually transmitted infections. Medication-assisted treatment should be readily available to all pregnant women identified with OUD to improve maternal and infant outcomes."}
{"id": "article-36546_32", "title": "Substance Use in Pregnancy -- Treatment / Management -- Breastfeeding", "content": "Women who breastfeed and \"room-in\" with their newborns require less pain medication after delivery. Breastfeeding is associated with a decreased severity of NOWS symptoms and\u00a0a decreased need for pharmacotherapy\u00a0for\u00a0affected newborns. [36] [37] However, it is not recommended when women use illicit substances, including marijuana, because traces can be found in breast milk. Few controlled studies exist on marijuana in breastfeeding women, and it is difficult to separate prenatal from breast milk exposure. Without data supporting its safety, ACOG and the American Academy of Pediatrics (AAP) regard abstaining as prudent. [38]", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Breastfeeding. Women who breastfeed and \"room-in\" with their newborns require less pain medication after delivery. Breastfeeding is associated with a decreased severity of NOWS symptoms and\u00a0a decreased need for pharmacotherapy\u00a0for\u00a0affected newborns. [36] [37] However, it is not recommended when women use illicit substances, including marijuana, because traces can be found in breast milk. Few controlled studies exist on marijuana in breastfeeding women, and it is difficult to separate prenatal from breast milk exposure. Without data supporting its safety, ACOG and the American Academy of Pediatrics (AAP) regard abstaining as prudent. [38]"}
{"id": "article-36546_33", "title": "Substance Use in Pregnancy -- Treatment / Management -- Breastfeeding", "content": "Women with hepatitis C\u00a0should breastfeed unless they have cracked or bleeding nipples, but it\u00a0is\u00a0generally contraindicated for mothers with HIV. [39] [40] However, the World Health Organization recommends that mothers infected with HIV in developing countries who are treated with\u00a0combined antiretroviral therapy (cART) should breastfeed their infants\u00a0because breast milk is likely\u00a0more nutritious than available alternatives.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Breastfeeding. Women with hepatitis C\u00a0should breastfeed unless they have cracked or bleeding nipples, but it\u00a0is\u00a0generally contraindicated for mothers with HIV. [39] [40] However, the World Health Organization recommends that mothers infected with HIV in developing countries who are treated with\u00a0combined antiretroviral therapy (cART) should breastfeed their infants\u00a0because breast milk is likely\u00a0more nutritious than available alternatives."}
{"id": "article-36546_34", "title": "Substance Use in Pregnancy -- Treatment / Management -- Breastfeeding", "content": "Occasionally, a new mother will feel uncomfortable breastfeeding, especially if she has a history of intimate partner violence.\u00a0Clinicians should respect and support her decision\u00a0to nourish her baby with formula.", "contents": "Substance Use in Pregnancy -- Treatment / Management -- Breastfeeding. Occasionally, a new mother will feel uncomfortable breastfeeding, especially if she has a history of intimate partner violence.\u00a0Clinicians should respect and support her decision\u00a0to nourish her baby with formula."}
{"id": "article-36546_35", "title": "Substance Use in Pregnancy -- Differential Diagnosis", "content": "The differential diagnosis\u00a0is based on the particular substance(s) being used during the pregnancy.", "contents": "Substance Use in Pregnancy -- Differential Diagnosis. The differential diagnosis\u00a0is based on the particular substance(s) being used during the pregnancy."}
{"id": "article-36546_36", "title": "Substance Use in Pregnancy -- Differential Diagnosis", "content": "If\u00a0the medical history, physical examination, validated screening, or biological testing reveals substance use, the\u00a0next\u00a0step is to distinguish between occasional or prescription usage and SUD. If a woman is diagnosed with SUD, she should be evaluated for single versus polysubstance use because the consequences and treatment differ, depending on the substances involved. The clinician must search for common comorbid conditions related to SUD, including sexually transmitted infections such as HIV. Individuals with SUD also have higher rates of\u00a0mental health disorders than the general population. Diagnosing\u00a0psychiatric conditions may be difficult before initiating SUD treatment due to overlapping symptoms. In addition, poor nutrition and dental hygiene often accompany SUD.", "contents": "Substance Use in Pregnancy -- Differential Diagnosis. If\u00a0the medical history, physical examination, validated screening, or biological testing reveals substance use, the\u00a0next\u00a0step is to distinguish between occasional or prescription usage and SUD. If a woman is diagnosed with SUD, she should be evaluated for single versus polysubstance use because the consequences and treatment differ, depending on the substances involved. The clinician must search for common comorbid conditions related to SUD, including sexually transmitted infections such as HIV. Individuals with SUD also have higher rates of\u00a0mental health disorders than the general population. Diagnosing\u00a0psychiatric conditions may be difficult before initiating SUD treatment due to overlapping symptoms. In addition, poor nutrition and dental hygiene often accompany SUD."}
{"id": "article-36546_37", "title": "Substance Use in Pregnancy -- Differential Diagnosis", "content": "Clinicians who listen carefully, perform a complete physical examination, and screen with a validated\u00a0instrument are more likely to diagnose SUD early and initiate appropriate treatment. Pregnant women with SUD must be evaluated for coexisting conditions\u00a0that can adversely impact the pregnancy if not diagnosed and promptly managed. A high index of suspicion for SUD will lead to early treatment and improved outcomes for both mother and her child.", "contents": "Substance Use in Pregnancy -- Differential Diagnosis. Clinicians who listen carefully, perform a complete physical examination, and screen with a validated\u00a0instrument are more likely to diagnose SUD early and initiate appropriate treatment. Pregnant women with SUD must be evaluated for coexisting conditions\u00a0that can adversely impact the pregnancy if not diagnosed and promptly managed. A high index of suspicion for SUD will lead to early treatment and improved outcomes for both mother and her child."}
{"id": "article-36546_38", "title": "Substance Use in Pregnancy -- Prognosis", "content": "Abstinence and medication-assisted treatment improve outcomes for pregnant women and their children. Pregnancy is a strong motivator for abstinence, and most women refrain from or decrease their use of tobacco, alcohol, marijuana, and cocaine by the second trimester.\u00a0Those with OUD receiving medication-assisted treatment, enrolled\u00a0in a comprehensive program\u00a0with behavioral counseling and psychosocial support, usually maintain sobriety until delivery. However, postpartum relapse is frequent, especially for tobacco, marijuana, and alcohol, with rates as high as 80% in the first year after giving birth. [8] Following delivery, a combination of sleep deprivation, hormonal shifts, and caring for an infant causes\u00a0stress, making ongoing recovery challenging. Postpartum unintentional overdoses contribute to maternal mortality, and women should be followed closely\u00a0during the first postpartum year. [41]", "contents": "Substance Use in Pregnancy -- Prognosis. Abstinence and medication-assisted treatment improve outcomes for pregnant women and their children. Pregnancy is a strong motivator for abstinence, and most women refrain from or decrease their use of tobacco, alcohol, marijuana, and cocaine by the second trimester.\u00a0Those with OUD receiving medication-assisted treatment, enrolled\u00a0in a comprehensive program\u00a0with behavioral counseling and psychosocial support, usually maintain sobriety until delivery. However, postpartum relapse is frequent, especially for tobacco, marijuana, and alcohol, with rates as high as 80% in the first year after giving birth. [8] Following delivery, a combination of sleep deprivation, hormonal shifts, and caring for an infant causes\u00a0stress, making ongoing recovery challenging. Postpartum unintentional overdoses contribute to maternal mortality, and women should be followed closely\u00a0during the first postpartum year. [41]"}
{"id": "article-36546_39", "title": "Substance Use in Pregnancy -- Complications", "content": "Tobacco use increases the risk of stillbirth, fetal growth restriction, decreased birth weight, prematurity, and sudden unexplained infant death. [42] [43] Smoking is associated with attention deficit/hyperactivity disorder in childhood, but studies confirming causation are lacking. [44]", "contents": "Substance Use in Pregnancy -- Complications. Tobacco use increases the risk of stillbirth, fetal growth restriction, decreased birth weight, prematurity, and sudden unexplained infant death. [42] [43] Smoking is associated with attention deficit/hyperactivity disorder in childhood, but studies confirming causation are lacking. [44]"}
{"id": "article-36546_40", "title": "Substance Use in Pregnancy -- Complications", "content": "No amount of alcohol is deemed safe during pregnancy, and\u00a0drinking may result in fetal alcohol syndrome (FAS) and congenital malformations. Like tobacco, alcohol may be perceived as safe and socially acceptable because it is legal. As many as 13.5% of pregnant women have consumed alcohol in the previous month, according to the Centers for Disease Control. Alcohol is a known teratogen, and FAS is the leading cause of preventable intellectual disability in the US. [22]", "contents": "Substance Use in Pregnancy -- Complications. No amount of alcohol is deemed safe during pregnancy, and\u00a0drinking may result in fetal alcohol syndrome (FAS) and congenital malformations. Like tobacco, alcohol may be perceived as safe and socially acceptable because it is legal. As many as 13.5% of pregnant women have consumed alcohol in the previous month, according to the Centers for Disease Control. Alcohol is a known teratogen, and FAS is the leading cause of preventable intellectual disability in the US. [22]"}
{"id": "article-36546_41", "title": "Substance Use in Pregnancy -- Complications", "content": "Marijuana is a federally banned substance in the US,\u00a0but legal in many states. Randomized, controlled studies during\u00a0pregnancy are lacking, but there is evidence of an association with stillbirth, decreased birth weight, and preterm birth. [45] [46] Direct causal evidence is lacking, but there is a concern about poorer cognitive outcomes in school-aged children. [38] One study reported that maternal marijuana use during pregnancy did not predict adverse neonatal outcomes after adjusting for concomitant tobacco use and other confounding factors. [47] However, a recent review and meta-analysis reported increased adverse outcomes in neonates exposed to marijuana in-utero. [48] These included a birth weight\u00a0under 2500 grams, decreased mean birth weight, small for gestational age, prematurity,\u00a0lower Apgar score at 1 minute, and\u00a0smaller mean head circumference. [48] ACOG and the AAP advise avoiding marijuana due to the possible neurodevelopmental impact on the developing fetus. [49]", "contents": "Substance Use in Pregnancy -- Complications. Marijuana is a federally banned substance in the US,\u00a0but legal in many states. Randomized, controlled studies during\u00a0pregnancy are lacking, but there is evidence of an association with stillbirth, decreased birth weight, and preterm birth. [45] [46] Direct causal evidence is lacking, but there is a concern about poorer cognitive outcomes in school-aged children. [38] One study reported that maternal marijuana use during pregnancy did not predict adverse neonatal outcomes after adjusting for concomitant tobacco use and other confounding factors. [47] However, a recent review and meta-analysis reported increased adverse outcomes in neonates exposed to marijuana in-utero. [48] These included a birth weight\u00a0under 2500 grams, decreased mean birth weight, small for gestational age, prematurity,\u00a0lower Apgar score at 1 minute, and\u00a0smaller mean head circumference. [48] ACOG and the AAP advise avoiding marijuana due to the possible neurodevelopmental impact on the developing fetus. [49]"}
{"id": "article-36546_42", "title": "Substance Use in Pregnancy -- Complications", "content": "Cocaine use is associated with maternal hypertension and placental abruption and may result in low birth weight, small for gestational age, and prematurity in neonates. [50] [51] Researchers have established a link between cocaine use and growth\u00a0deceleration involving all parameters, with a more pronounced effect in late gestation. [52] Amphetamines are associated with increased maternal and fetal morbidity and mortality, including maternal hypertension, preeclampsia, placental\u00a0abruption, fetal demise, and neonatal death. [53]", "contents": "Substance Use in Pregnancy -- Complications. Cocaine use is associated with maternal hypertension and placental abruption and may result in low birth weight, small for gestational age, and prematurity in neonates. [50] [51] Researchers have established a link between cocaine use and growth\u00a0deceleration involving all parameters, with a more pronounced effect in late gestation. [52] Amphetamines are associated with increased maternal and fetal morbidity and mortality, including maternal hypertension, preeclampsia, placental\u00a0abruption, fetal demise, and neonatal death. [53]"}
{"id": "article-36546_43", "title": "Substance Use in Pregnancy -- Complications", "content": "Opioids, both illicit and prescribed, can cause NOWS, which affects the newborn's central nervous, autonomic, respiratory, and gastrointestinal systems and may\u00a0lead to prolonged hospitalization. [54] Early signs and symptoms include irritability, poor feeding, temperature instability, and difficulty sleeping.\u00a0Prenatal opioid use also increases the risk of low birth weight and neonates who are small for gestational age. [55] [56] [57]", "contents": "Substance Use in Pregnancy -- Complications. Opioids, both illicit and prescribed, can cause NOWS, which affects the newborn's central nervous, autonomic, respiratory, and gastrointestinal systems and may\u00a0lead to prolonged hospitalization. [54] Early signs and symptoms include irritability, poor feeding, temperature instability, and difficulty sleeping.\u00a0Prenatal opioid use also increases the risk of low birth weight and neonates who are small for gestational age. [55] [56] [57]"}
{"id": "article-36546_44", "title": "Substance Use in Pregnancy -- Complications", "content": "Legal\u00a0issues can also occur with substance use during pregnancy. Eighteen states in the US define substance use as child abuse, and three consider it grounds for commitment. Many\u00a0women fear arrest, prosecution, and loss of custody and therefore avoid prenatal care or do not disclose their substance use to their medical providers. Some states mandate reporting\u00a0all illicit or prescribed substance use, including marijuana and medication-assisted treatment, to Child Protective Services. Clinicians must know their local testing and reporting requirements\u00a0and\u00a0share this information with their pregnant patients while advocating for holistic and comprehensive care. Criminalizing substance use will not lead to improved clinical outcomes for mothers\u00a0or their children.", "contents": "Substance Use in Pregnancy -- Complications. Legal\u00a0issues can also occur with substance use during pregnancy. Eighteen states in the US define substance use as child abuse, and three consider it grounds for commitment. Many\u00a0women fear arrest, prosecution, and loss of custody and therefore avoid prenatal care or do not disclose their substance use to their medical providers. Some states mandate reporting\u00a0all illicit or prescribed substance use, including marijuana and medication-assisted treatment, to Child Protective Services. Clinicians must know their local testing and reporting requirements\u00a0and\u00a0share this information with their pregnant patients while advocating for holistic and comprehensive care. Criminalizing substance use will not lead to improved clinical outcomes for mothers\u00a0or their children."}
{"id": "article-36546_45", "title": "Substance Use in Pregnancy -- Deterrence and Patient Education", "content": "Patient education regarding maternal and neonatal complications\u00a0of substance use in pregnancy is essential. Comprehensive prenatal and postnatal care, including behavioral counseling and psychosocial support, improves clinical outcomes. [14] Childbearing-aged women should receive information about the dangers of prenatal substance use, including alcohol, tobacco, and marijuana because\u00a0many pregnancies are unplanned. For women with OUD, initiating medication-assisted treatment before pregnancy is\u00a0a recommended public health approach.", "contents": "Substance Use in Pregnancy -- Deterrence and Patient Education. Patient education regarding maternal and neonatal complications\u00a0of substance use in pregnancy is essential. Comprehensive prenatal and postnatal care, including behavioral counseling and psychosocial support, improves clinical outcomes. [14] Childbearing-aged women should receive information about the dangers of prenatal substance use, including alcohol, tobacco, and marijuana because\u00a0many pregnancies are unplanned. For women with OUD, initiating medication-assisted treatment before pregnancy is\u00a0a recommended public health approach."}
{"id": "article-36546_46", "title": "Substance Use in Pregnancy -- Deterrence and Patient Education", "content": "Women whose\u00a0newborns are at risk for NOWS benefit from\u00a0learning what to expect after delivery. Nurses and other clinicians can discuss newborn withdrawal symptoms, comfort measures, breastfeeding, pharmacotherapy options, and the need for\u00a0close observation. Many labor and delivery units offer prenatal tours to mothers with OUD to prepare them for their perinatal experience.", "contents": "Substance Use in Pregnancy -- Deterrence and Patient Education. Women whose\u00a0newborns are at risk for NOWS benefit from\u00a0learning what to expect after delivery. Nurses and other clinicians can discuss newborn withdrawal symptoms, comfort measures, breastfeeding, pharmacotherapy options, and the need for\u00a0close observation. Many labor and delivery units offer prenatal tours to mothers with OUD to prepare them for their perinatal experience."}
{"id": "article-36546_47", "title": "Substance Use in Pregnancy -- Deterrence and Patient Education", "content": "Patient education, counseling, and monitoring do not end with delivery. Women with SUD\u00a0are at high risk for postpartum relapse and\u00a0must be educated\u00a0about the\u00a0dangers of resuming substance use after delivery. They should be screened and closely monitored, especially during the first postpartum year. Continued medication-assisted treatment and consultation with substance use specialists and behavior therapists will help achieve\u00a0optimal outcomes. [8] Broadly defined, patient education includes information and access to resources for transportation, safe housing, food security, childcare, and contraception. Trauma-informed counseling and peer recovery support groups can also improve the chances of\u00a0sobriety following delivery. [58]", "contents": "Substance Use in Pregnancy -- Deterrence and Patient Education. Patient education, counseling, and monitoring do not end with delivery. Women with SUD\u00a0are at high risk for postpartum relapse and\u00a0must be educated\u00a0about the\u00a0dangers of resuming substance use after delivery. They should be screened and closely monitored, especially during the first postpartum year. Continued medication-assisted treatment and consultation with substance use specialists and behavior therapists will help achieve\u00a0optimal outcomes. [8] Broadly defined, patient education includes information and access to resources for transportation, safe housing, food security, childcare, and contraception. Trauma-informed counseling and peer recovery support groups can also improve the chances of\u00a0sobriety following delivery. [58]"}
{"id": "article-36546_48", "title": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes", "content": "Caring for women with substance use during pregnancy can be rewarding, challenging, complex, and time-consuming. A holistic approach to comprehensive care requires an interprofessional team. Nurses, nurse practitioners, physician assistants, physicians, midwives, social workers, pharmacists, and mental health\u00a0and addiction medicine specialists who work together as a cohesive interprofessional team can\u00a0improve outcomes for mothers and their children. Prenatal screening for substance use can be performed by nursing staff in the office setting.\u00a0Nurses can also educate pregnant women about substance use, medication-assisted treatment, NOWS, and the advantages of breastfeeding.", "contents": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes. Caring for women with substance use during pregnancy can be rewarding, challenging, complex, and time-consuming. A holistic approach to comprehensive care requires an interprofessional team. Nurses, nurse practitioners, physician assistants, physicians, midwives, social workers, pharmacists, and mental health\u00a0and addiction medicine specialists who work together as a cohesive interprofessional team can\u00a0improve outcomes for mothers and their children. Prenatal screening for substance use can be performed by nursing staff in the office setting.\u00a0Nurses can also educate pregnant women about substance use, medication-assisted treatment, NOWS, and the advantages of breastfeeding."}
{"id": "article-36546_49", "title": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes", "content": "Many hospitals employ the LDRP model, where the same nurses care for the mother during labor, delivery, recovery, and postpartum.\u00a0Nurses are often the first to notice a new mother having difficulty caring for her newborn, especially if experiencing side effects of medication-assisted treatment, such as\u00a0falling asleep while holding her child. Pregnant women, due to a greater volume of distribution and rate of metabolism, often require more methadone during pregnancy, and the dose\u00a0might need adjustment after delivery. [32] An astute nurse observes maternal medication side effects\u00a0and early signs of neonatal withdrawal. Everyone who cares for the mother-infant dyad is part of the team.", "contents": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes. Many hospitals employ the LDRP model, where the same nurses care for the mother during labor, delivery, recovery, and postpartum.\u00a0Nurses are often the first to notice a new mother having difficulty caring for her newborn, especially if experiencing side effects of medication-assisted treatment, such as\u00a0falling asleep while holding her child. Pregnant women, due to a greater volume of distribution and rate of metabolism, often require more methadone during pregnancy, and the dose\u00a0might need adjustment after delivery. [32] An astute nurse observes maternal medication side effects\u00a0and early signs of neonatal withdrawal. Everyone who cares for the mother-infant dyad is part of the team."}
{"id": "article-36546_50", "title": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes", "content": "Many programs conduct multidisciplinary rounds regularly, with\u00a0professionals from obstetrics, pediatrics, pharmacy, and social work discussing the care of all mothers and their newborns. Social workers assist with assessing the social determinants of health, including housing, food insecurity, and transportation, and preparing mothers for the possible involvement of Child Protective Services.", "contents": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes. Many programs conduct multidisciplinary rounds regularly, with\u00a0professionals from obstetrics, pediatrics, pharmacy, and social work discussing the care of all mothers and their newborns. Social workers assist with assessing the social determinants of health, including housing, food insecurity, and transportation, and preparing mothers for the possible involvement of Child Protective Services."}
{"id": "article-36546_51", "title": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes", "content": "A model perinatal program at the Dartmouth-Hitchcock Medical Center combines\u00a0midwifery services\u00a0and\u00a0addiction treatment. This model provides specialized care for women during pregnancy and the postpartum year\u00a0and recognizes this population's unique and challenging needs. The program has led to\u00a0better access to prenatal care, continuity of care, and family planning services. [59]", "contents": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes. A model perinatal program at the Dartmouth-Hitchcock Medical Center combines\u00a0midwifery services\u00a0and\u00a0addiction treatment. This model provides specialized care for women during pregnancy and the postpartum year\u00a0and recognizes this population's unique and challenging needs. The program has led to\u00a0better access to prenatal care, continuity of care, and family planning services. [59]"}
{"id": "article-36546_52", "title": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional healthcare team can\u00a0improve\u00a0care for pregnant women with substance use and SUD. SUD is a complex medical condition requiring empathy, knowledge, and skills from\u00a0a team of caregivers working together. Implementing universal screening, overcoming barriers to treatment, addressing psychosocial needs,\u00a0establishing an early diagnosis, and initiating medication-assisted treatment when\u00a0appropriate will result in healthier outcomes for mothers and their children.", "contents": "Substance Use in Pregnancy -- Enhancing Healthcare Team Outcomes. The interprofessional healthcare team can\u00a0improve\u00a0care for pregnant women with substance use and SUD. SUD is a complex medical condition requiring empathy, knowledge, and skills from\u00a0a team of caregivers working together. Implementing universal screening, overcoming barriers to treatment, addressing psychosocial needs,\u00a0establishing an early diagnosis, and initiating medication-assisted treatment when\u00a0appropriate will result in healthier outcomes for mothers and their children."}
{"id": "article-36546_53", "title": "Substance Use in Pregnancy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Substance Use in Pregnancy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}